Sinclair Pharma Regulatory News (SPH)

Sinclair Pharma plc

Additional listing

London, 30 March 2017 Sinclair Pharma plc (SPH.L), ("Sinclair" or the "Company") the international aesthetics company, announces that 1,570,510 new ordinary shares of 1p each (the "New Ordinary Shares") have been issued and allotted to Christophe Foucher, former COO, in settlement of his severance package as previously announced on 1 September 2016.

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 5 April 2017 and, when issued, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

Following admission of the New Ordinary Shares, Sinclair will have 503,768,952 ordinary shares of 1p in issue.

This announcement contains inside information. The person responsible for arranging for the release of this announcement on behalf of Sinclair is Alan Olby, Chief Financial Officer.

For further information please contact:

Notes to Editors:

About Sinclair Pharma plc 

Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. Sinclair has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors. For more information, please visit www.sinclairpharma.com